Dosing & Uses
Dosage Forms & Strengths
intra-articular injection (prefilled syringe)
- 16mg/2mL (Synvisc)
- 30mg/2mL (Orthovisc)
- 48mg/6mL (Synvisc-One)
- 88mg/4mL (Monovisc)
Osteoarthritis of the Knee
Indicated for treatment of pain in osteoarthritis of the knee
Synvisc: Inject intra-articularly 16 mg (2 mL) to affected knee qWeek for 3 weeks
Synvisc-One: Inject intra-articularly 48 mg (6 mL) to affected knee once as a single injection
Orthovisc: Inject intr-articularly 30 mg (2 mL) to affected knee qWeek for 3 weeks
Monovisc: Inject intra-articularly 88 mg (4 mL) to affected knee once as a single injection
Orphan designation for emphysema due to alpha1-antitrypsin deficiency
- Gerard M. Turino, MD; Division of Pulmonary, Critical Care & Sleep Medicine; Mt. Sinai Roosevelt Hospital Center; New York, New York 10019
Safety and efficacy not established
Skin discoloration (33-78%)
Increased blood pressure (4%)
Injection site pain (3%)
Limb pain (1%)
Joint effusion (2%)
Hypersensitivity to hyaluronate preparations, avian-derived products (eg, eggs, feathers, poultry), gram-positive bacterial proteins
Do not inject in knees with infection or skin diseases in area of injection site or joint
Transient increased inflammation in injected knee may occur
Avoid strenuous activity or prolonged (>1 hr) weight-bearing activities (eg, running, tennis) within 48 hr following injection
Pain relief may not be evident until after 3rd injection
Remove joint effusion, if present, before injection
Not for injection intra-articular into synovium
Pregnancy & Lactation
Pregnancy Category: Not tested in pregnant women
Lactation: Unknown whether distributed in breast milk, caution advised
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
When injected intra-arterially, supplements joint cushioning to temporarily provide pain relief caused by osteoarthritis
High molecular weight polysaccharide composed of repeating disaccharide units of sodium glucuronate and N-acetylglucosamine; derived from bacterial cells
Concomitant use of disinfectants containing quaternary ammonium salts (eg, benzalkonium chloride) for skin preparation can precipitate in presence of hyaluronic acid
Use strict aseptic injection technique
Inject the full contents of single syringe intra-articularly into 1 knee only; if treatment is bilateral, a separate syringe should be used for each knee
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.